Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro

Journal of Proteome Research

Volumn 11, Issue 4, 2012, Pages 2452-2466

  Ummanni, Ramesh ^a,b   Barreto, Frederico ^a   Venz, Simone ^c   Scharf, Christian ^c   Barett, Christine ^a   Mannsperger, Heiko A ^d   Brase, Jan Christoph ^d   Kuner, Ruprecht ^d   Schlomm, Thorsten ^a   Sauter, Guido ^a   Sültmann, Holger ^d   Korf, Ulrike ^d   Bokemeyer, Carsten ^a   Walther, Reinhard ^c   Brümmendorf, Tim H ^a,e   Balabanov, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

cell proliferation; peroxiredoxin; prostate cancer; proteomics; TMPRSS2 ERG

Indexed keywords

PEROXIREDOXIN 3; PEROXIREDOXIN 4; PROTEOME;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; GENE FUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; HUMANS; MALE; PEROXIREDOXIN III; PEROXIREDOXINS; PROSTATE; PROSTATIC NEOPLASMS; PROTEOME; PROTEOMICS;

EID: 84859587479     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr201172n     Document Type: Article

References (51)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer Statistics CA: Cancer J. Clin. 2010, 60 (5) 277-300
2. Hsing, A. W.; Chokkalingam, A. P. Prostate cancer epidemiology Front. Biosci. 2006, 11, 1388-413
3. Labrie, F.; Candas, B.; Cusan, L.; Gomez, J. L.; Belanger, A.; Brousseau, G.; Chevrette, E.; Levesque, J. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial Prostate 2004, 59 (3) 311-8
4. Andriole, G. L.; Crawford, E. D.; Grubb, R. L., 3rd; Buys, S. S.; Chia, D.; Church, T. R.; Fouad, M. N.; Gelmann, E. P.; Kvale, P. A.; Reding, D. J.; Weissfeld, J. L.; Yokochi, L. A.; OBrien, B.; Clapp, J. D.; Rathmell, J. M.; Riley, T. L.; Hayes, R. B.; Kramer, B. S.; Izmirlian, G.; Miller, A. B.; Pinsky, P. F.; Prorok, P. C.; Gohagan, J. K.; Berg, C. D. Mortality results from a randomized prostate-cancer screening trial N. Engl. J. Med. 2009, 360 (13) 1310-9
5. Chou, R.; Croswell, J. M.; Dana, T.; Bougatsos, C.; Blazina, I.; Fu, R.; Gleitsmann, K.; Koenig, H. C.; Lam, C.; Maltz, A.; Rugge, J. B.; Lin, K. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force Ann. Intern. Med. 2011, 155 (11) 762-71
6. Schroder, F. H.; Hugosson, J.; Roobol, M. J.; Tammela, T. L.; Ciatto, S.; Nelen, V.; Kwiatkowski, M.; Lujan, M.; Lilja, H.; Zappa, M.; Denis, L. J.; Recker, F.; Berenguer, A.; Maattanen, L.; Bangma, C. H.; Aus, G.; Villers, A.; Rebillard, X.; van der Kwast, T.; Blijenberg, B. G.; Moss, S. M.; de Koning, H. J.; Auvinen, A. Screening and prostate-cancer mortality in a randomized European study N. Engl. J. Med. 2009, 360 (13) 1320-8
7. Khan, A. P.; Poisson, L. M.; Bhat, V. B.; Fermin, D.; Zhao, R.; Kalyana-Sundaram, S.; Michailidis, G.; Nesvizhskii, A. I.; Omenn, G. S.; Chinnaiyan, A. M.; Sreekumar, A. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer Mol. Cell. Proteomics 2010, 9 (2) 298-312
8. Maher, C. A.; Kumar-Sinha, C.; Cao, X.; Kalyana-Sundaram, S.; Han, B.; Jing, X.; Sam, L.; Barrette, T.; Palanisamy, N.; Chinnaiyan, A. M. Transcriptome sequencing to detect gene fusions in cancer Nature 2009, 458 (7234) 97-101
9. Gopalan, A.; Leversha, M. A.; Satagopan, J. M.; Zhou, Q.; Al-Ahmadie, H. A.; Fine, S. W.; Eastham, J. A.; Scardino, P. T.; Scher, H. I.; Tickoo, S. K.; Reuter, V. E.; Gerald, W. L. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy Cancer Res. 2009, 69 (4) 1400-6
10. Tomlins, S. A.; Mehra, R.; Rhodes, D. R.; Cao, X.; Wang, L.; Dhanasekaran, S. M.; Kalyana-Sundaram, S.; Wei, J. T.; Rubin, M. A.; Pienta, K. J.; Shah, R. B.; Chinnaiyan, A. M. Integrative molecular concept modeling of prostate cancer progression Nat. Genetics 2007, 39 (1) 41-51
11. Tomlins, S. A.; Rhodes, D. R.; Perner, S.; Dhanasekaran, S. M.; Mehra, R.; Sun, X. W.; Varambally, S.; Cao, X.; Tchinda, J.; Kuefer, R.; Lee, C.; Montie, J. E.; Shah, R. B.; Pienta, K. J.; Rubin, M. A.; Chinnaiyan, A. M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 2005, 310 (5748) 644-8
12. Kumar-Sinha, C.; Tomlins, S. A.; Chinnaiyan, A. M. Recurrent gene fusions in prostate cancer Nat. Rev.: Cancer 2008, 8 (7) 497-511
13. Tomlins, S. A.; Laxman, B.; Dhanasekaran, S. M.; Helgeson, B. E.; Cao, X.; Morris, D. S.; Menon, A.; Jing, X.; Cao, Q.; Han, B.; Yu, J.; Wang, L.; Montie, J. E.; Rubin, M. A.; Pienta, K. J.; Roulston, D.; Shah, R. B.; Varambally, S.; Mehra, R.; Chinnaiyan, A. M. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer Nature 2007, 448 (7153) 595-9
14. Pang, J.; Liu, W. P.; Liu, X. P.; Li, L. Y.; Fang, Y. Q.; Sun, Q. P.; Liu, S. J.; Li, M. T.; Su, Z. L.; Gao, X. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis J. Proteome Res. 2010, 9 (1) 216-26
15. Meehan, K. L.; Holland, J. W.; Dawkins, H. J. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer Prostate 2002, 50 (1) 54-63
16. Everley, P. A.; Bakalarski, C. E.; Elias, J. E.; Waghorne, C. G.; Beausoleil, S. A.; Gerber, S. A.; Faherty, B. K.; Zetter, B. R.; Gygi, S. P. Enhanced analysis of metastatic prostate cancer using stable isotopes and high mass accuracy instrumentation J. Proteome Res. 2006, 5 (5) 1224-31
17. Lexander, H.; Palmberg, C.; Hellman, U.; Auer, G.; Hellstrom, M.; Franzen, B.; Jornvall, H.; Egevad, L. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer Proteomics 2006, 6 (15) 4370-80
18. Wozny, W.; Schroer, K.; Schwall, G. P.; Poznanovic, S.; Stegmann, W.; Dietz, K.; Rogatsch, H.; Schaefer, G.; Huebl, H.; Klocker, H.; Schrattenholz, A.; Cahill, M. A. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3 Proteomics 2007, 7 (2) 313-22
19. Lin, J. F.; Xu, J.; Tian, H. Y.; Gao, X.; Chen, Q. X.; Gu, Q.; Xu, G. J.; Song, J. D.; Zhao, F. K. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis Int. J. Cancer 2007, 121 (12) 2596-605
20. Ummanni, R.; Mundt, F.; Pospisil, H.; Venz, S.; Scharf, C.; Barett, C.; Falth, M.; Kollermann, J.; Walther, R.; Schlomm, T.; Sauter, G.; Bokemeyer, C.; Sultmann, H.; Schuppert, A.; Brummendorf, T. H.; Balabanov, S. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform PLoS One 2011, 6 (2) e16833
21. Schlomm, T.; Luebke, A. M.; Sultmann, H.; Hellwinkel, O. J.; Sauer, U.; Poustka, A.; David, K. A.; Chun, F. K.; Haese, A.; Graefen, M.; Erbersdobler, A.; Huland, H. Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis Int. J. Oncol. 2005, 27 (3) 713-20
22. Jhavar, S.; Reid, A.; Clark, J.; Kote-Jarai, Z.; Christmas, T.; Thompson, A.; Woodhouse, C.; Ogden, C.; Fisher, C.; Corbishley, C.; De-Bono, J.; Eeles, R.; Brewer, D.; Cooper, C. Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays J. Mol. Diagn. 2008, 10 (1) 50-7
23. Huang da, W.; Sherman, B. T.; Lempicki, R. A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists Nucleic Acids Res. 2009, 37 (1) 1-13
24. Huang da, W.; Sherman, B. T.; Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources Nature Protoc. 2009, 4 (1) 44-57
25. Loebke, C.; Sueltmann, H.; Schmidt, C.; Henjes, F.; Wiemann, S.; Poustka, A.; Korf, U. Infrared-based protein detection arrays for quantitative proteomics Proteomics 2007, 7 (4) 558-64
26. Mannsperger, H. A.; Gade, S.; Henjes, F.; Beissbarth, T.; Korf, U. RPPanalyzer: Analysis of reverse-phase protein array data Bioinformatics 2010, 26 (17) 2202-3
27. Ganter, B.; Wille, R., Applications of Combinatorics and Graph Theory to the Biological and Social Sciences; Springer: New York, 1989.
28. Kaytoue, M.; Duplessis, S.; Kuznetsov, S.; Napoli, A. In Two FCA-Based Methods for Mining Gene Expression Data Formal Concept Analysis; Ferré, S.; Rudolph, S., Eds.; Springer: Berlin/Heidelberg, 2009; Vol. 5548, pp 251-266.
29. Motameny, S.; Versmold, B.; Schmutzler, R. Formal concept analysis for the identification of combinatorial biomarkers in breast cancer. In Proceedings of the 6th International Conference on Formal Concept Analysis; Springer-Verlag: Montreal, Canada, 2008; pp 229-240.
30. Blachon, S.; Pensa, R. G.; Besson, J.; Robardet, C.; Boulicaut, J. F.; Gandrillon, O. Clustering formal concepts to discover biologically relevant knowledge from gene expression data In Silico Biol. 2007, 7 (4-5) 467-83
31. Weber, K.; Mock, U.; Petrowitz, B.; Bartsch, U.; Fehse, B. Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis Gene Ther. 2010, 17 (4) 511-20
32. Balabanov, S.; Gontarewicz, A.; Keller, G.; Raddrizzani, L.; Braig, M.; Bosotti, R.; Moll, J.; Jost, E.; Barett, C.; Rohe, I.; Bokemeyer, C.; Holyoake, T. L.; Brummendorf, T. H. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro PLoS One 2011, 6 (4) e19164
33. Ummanni, R.; Jost, E.; Braig, M.; Lohmann, F.; Mundt, F.; Barett, C.; Schlomm, T.; Sauter, G.; Senff, T.; Bokemeyer, C.; Sultmann, H.; Meyer-Schwesinger, C.; Brummendorf, T. H.; Balabanov, S. Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation Mol. Cancer 2011, 10, 129
34. Hanash, S.; Taguchi, A. The grand challenge to decipher the cancer proteome Nat. Rev.: Cancer 2010, 10 (9) 652-60
35. Balabanov, S.; Gontarewicz, A.; Ziegler, P.; Hartmann, U.; Kammer, W.; Copland, M.; Brassat, U.; Priemer, M.; Hauber, I.; Wilhelm, T.; Schwarz, G.; Kanz, L.; Bokemeyer, C.; Hauber, J.; Holyoake, T. L.; Nordheim, A.; Brummendorf, T. H. Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach Blood 2007, 109 (4) 1701-11
36. Peng, X. Q.; Wang, F.; Geng, X.; Zhang, W. M. Current advances in tumor proteomics and candidate biomarkers for hepatic cancer Expert Rev. Proteomics 2009, 6 (5) 551-61
37. Gao, X.; Pang, J.; Li, L. Y.; Liu, W. P.; Di, J. M.; Sun, Q. P.; Fang, Y. Q.; Liu, X. P.; Pu, X. Y.; He, D.; Li, M. T.; Su, Z. L.; Li, B. Y. Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer Oncogene 2010, 29 (32) 4555-66
38. Garbis, S. D.; Tyritzis, S. I.; Roumeliotis, T.; Zerefos, P.; Giannopoulou, E. G.; Vlahou, A.; Kossida, S.; Diaz, J.; Vourekas, S.; Tamvakopoulos, C.; Pavlakis, K.; Sanoudou, D.; Constantinides, C. A. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry J. Proteome Res. 2008, 7 (8) 3146-58
39. Weber, M. J.; Gioeli, D. Ras signaling in prostate cancer progression J. Cell. Biochem. 2004, 91 (1) 13-25
40. Morgan, T. M.; Koreckij, T. D.; Corey, E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway Curr. Cancer Drug Targets 2009, 9 (2) 237-49
41. Gan, Y.; Shi, C.; Inge, L.; Hibner, M.; Balducci, J.; Huang, Y. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells Oncogene 2010, 29 (35) 4947-58
42. Clegg, N. J.; Couto, S. S.; Wongvipat, J.; Hieronymus, H.; Carver, B. S.; Taylor, B. S.; Ellwood-Yen, K.; Gerald, W. L.; Sander, C.; Sawyers, C. L. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors PLoS One 2011, 6 (3) e17449
43. Jenkins, R. B.; Qian, J.; Lieber, M. M.; Bostwick, D. G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization Cancer Res. 1997, 57 (3) 524-31
44. Basu, A.; Banerjee, H.; Rojas, H.; Martinez, S. R.; Roy, S.; Jia, Z.; Lilly, M. B.; De Leon, M.; Casiano, C. A. Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4 Prostate 2011, 71 (7) 755-65
45. Tomlins, S. A.; Bjartell, A.; Chinnaiyan, A. M.; Jenster, G.; Nam, R. K.; Rubin, M. A.; Schalken, J. A. ETS gene fusions in prostate cancer: from discovery to daily clinical practice European Urology 2009, 56 (2) 275-86
46. Minner, S.; Enodien, M.; Sirma, H.; Luebke, A. M.; Krohn, A.; Mayer, P. S.; Simon, R.; Tennstedt, P.; Muller, J.; Scholz, L.; Brase, J. C.; Liu, A. Y.; Schluter, H.; Pantel, K.; Schumacher, U.; Bokemeyer, C.; Steuber, T.; Graefen, M.; Sauter, G.; Schlomm, T. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy Clin. Cancer Res. 2011, 17 (18) 5878-88
47. Chua, P. J.; Lee, E. H.; Yu, Y.; Yip, G. W.; Tan, P. H.; Bay, B. H. Silencing the Peroxiredoxin III gene inhibits cell proliferation in breast cancer Int. J. Oncol. 2010, 36 (2) 359-64
48. Nonn, L.; Berggren, M.; Powis, G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis Mol. Cancer Res. 2003, 1 (9) 682-9
49. Wonsey, D. R.; Zeller, K. I.; Dang, C. V. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (10) 6649-54
50. Haridas, V.; Ni, J.; Meager, A.; Su, J.; Yu, G. L.; Zhai, Y.; Kyaw, H.; Akama, K. T.; Hu, J.; Van Eldik, L. J.; Aggarwal, B. B. TRANK, a novel cytokine that activates NF-kappa B and c-Jun N-terminal kinase J. Immunol. 1998, 161 (1) 1-6
51. El-Haibi, C. P.; Singh, R.; Sharma, P. K.; Singh, S.; Lillard, J. W., Jr. CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation Cell Proliferation 2011, 44 (4) 311-9